Introduction
Platelets are small anucleate fragments derived from megakaryocytes that are vital for maintaining hemostasis. A growing body of evidence has established that platelets also contribute to other pathophysiological processes, including atherogenesis, 1 inflammation, 2 wound repair, 3 angiogenesis, 4 blood-lymphatic vessel separation 5 and cancer metastasis. 6 A common underlying theme is that platelets must transition from a 'resting' to an 'activated'
state to contribute to each of these processes. Thus, understanding how platelets undergo this transition has broad implications for a number of diseases. Equally important, but less well understood, are the mechanisms that prevent unwarranted platelet activation and limit thrombus size. Under normal physiological conditions platelets are maintained in a resting state by transient inhibitory signals that prevent unnecessary activation, whilst at the same time allowing platelets to fully respond to vascular injury when required. Two of the most powerful platelet inhibitors are prostacyclin (PGI 2 ) and nitric oxide (NO), which are released by healthy endothelium. They act by elevating intracellular cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP) levels in the platelet via adenylate cyclase and soluble guanylate cyclase, respectively. These cyclic nucleotides in turn activate protein kinase A (PKA) and PKG, respectively, which phosphorylate key targets and inhibit platelet activation ( Figure 1 ). 8 Immunoreceptor tyrosine-based inhibition motif (ITIM)-containing receptors provide a more specialized, cell-intrinsic inhibition, compared with PGI 2 and NO, by primarily targeting ITAM-containing receptors ( Figure 2 ). The prototype of this family of receptors is the immune receptor FcRIIB, which inhibits signaling from the ITAM-containing B cell receptor complex following ligand-mediated co-clustering of the two receptors. 9 Structurally, all ITIM-containing receptors belong to the immunoglobulin receptor superfamily, and carry at least one consensus ITIM sequence in their cytoplasmic tail, defined as I/V/LxYxxL/V (x represents any amino acid), in reference to the previously described ITAM (consensus sequence YxxI/Lx [6] [7] [8] [9] [10] [11] [12] YxxI/L). A third ITIM-like motif, termed an immunoreceptor tyrosine-based switch motif (ITSM, consensus sequence TxYxxV/I), 11 was subsequently described that confers activating and/or inhibitory properties to a receptor, depending on the associated signaling proteins.
ITSMs were first identified in the signaling lymphocyte adhesion molecule (SLAM) CD150, which has both activating and inhibitory functions. 12 SLAM family proteins recruit members of the SLAM-adaptor protein (SAP) family, an interaction that is enhanced, but not dependent on, ITSM phosphorylation. 13 When SAP proteins associate with SLAM family receptors activating signals generally predominate, through recruitment of SFKs, whilst the absence of SAP adaptors allows phosphatase recruitment to promote inhibitory signaling. 13 The abundance and availability of the SAP adaptors adds a layer of complexity to ITSMmediated control of SLAM receptor activity. ITSMs are often found in close proximity to ITIMs, facilitating interactions with SH2 domain-containing phosphatases, and contributing to the inhibitory function of ITIM-containing receptors.
For many years, PECAM-1 (also referred to as CD31) was the only known ITIMcontaining receptor in platelets. [14] [15] [16] [17] However, with the advent of proteomics and transcriptomics, several other structurally distinct ITIM-containing receptors were identified in platelets. These regulate various aspects of platelet function and include G6b-B, 18, 19 TREM-like transcript (TLT-1), 20 carcinoembryonic antigen-related cell adhesion molecule 1 and 2 (CEACAM1 and CEACAM2) 21, 22 and LILRB2 (also referred to as PIR-B), 23 structural features of which are summarized in Figure 3 , and phenotypes of knockout (KO) and transgenic mouse models in Table 1 . In addition, the inhibitory collagen-binding ITIMcontaining receptor LAIR-1, also shown in Figure 3 , has been identified in immature With the recent increase in the number of ITIM-containing receptors reported in platelets and their diverse functional roles in regulating platelet homeostasis, we compiled this review to summarize structural and functional features, landmark discoveries, controversies and intriguing new findings that dispel the notion of ITIM-containing receptors as simply inhibitors of ITAM-mediated signaling (Figure 4 ). We focus on PECAM-1, G6b-B and TLT-1, which together illustrate the old, the new and the non-conventional members of this family of receptors in platelets. Adjacent to the transmembrane domain of human PECAM-1 on the cytosolic side is a palmitoylation site (C595) followed by a proline-rich region (PRR), ITIM (Y663) and ITSM (Y686) -C594, Y662 and Y685, respectively, in murine PECAM-1 ( Figure 3 and Table 2 ). 
PECAM-1 -the prototype

Structure and function
Mouse Models
Studies using PECAM-1 KO (Pecam1
) mice have greatly enhanced our understanding of the physiological functions of PECAM-1. Platelets isolated from Pecam1 -/-mice display potentiated aggregation, Ca 2+ release and secretion in response to collagen, the GPVI-specific ligand collagen-related peptide (CRP) and thrombin. 17, 43 Paradoxically, platelets from
Pecam1
-/-mice spread less well on a fibrinogen-coated surface and exhibit reduced clot retraction compared with control platelets, suggesting that PECAM-1 is a positive regulator of  IIb  3 -mediated outside-in signaling. 45 However, the mechanism underlying this potentiation of integrin-mediated responses in platelets remains unclear, only a reduction in focal adhesion kinase phosphorylation has been shown. The observed phenotype could therefore simply be due to up-regulation of compensatory mechanisms that limit platelet spreading on fibrinogen in the absence of PECAM-1. Further work is needed to determine the exact role of PECAM-1 in regulating  IIb  3 signaling and function.
These changes in platelet reactivity result in enhanced thrombus formation following laser-and ferric chloride-induced injury in mesenteric arterioles and carotid arteries of mice, respectively, with both onset of thrombus formation and thrombus stability being increased. 35 Use of bone marrow chimeric mice proved this to be primarily due to loss of platelet, rather than endothelial PECAM-1. 35 In contrast, tail bleeding times were increased in Pecam1
-/-mice, due to a loss of endothelial PECAM-1. 47 This suggests both positive and negative roles of PECAM-1 in thrombosis and hemostasis, respectively, dependent upon the lineage of cell expression. It should be noted that a separate study reported no difference in thrombus formation or bleeding between wild-type and Pecam1 -/-mice following photochemicalinduced injury of arterioles and venules and tail-bleeding assay. 48 However, there is little if any collagen exposure in this thrombosis model, instead it is predominantly dependent upon reactive oxygen species-mediated damage of endothelial cells. 49 In contrast, ferric chloride injury results in endothelial denudation and exposure of the basement membrane therefore increasing reliance upon GPVI-mediated platelet activation. 50 Lack of standardization and variability between different models likely accounts for the discrepancies between studies, 51 but also highlights the specialized role of PECAM-1 in these processes. 43 Regardless of these controversies, evidence clearly demonstrates a vital role for PECAM-1 in regulating platelet activation and function, involving both canonical and non-canonical ITIM-mediated signaling mechanisms.
With regards to platelet turnover, Pecam1 -/-mice have normal platelet counts, 47, 52 but exhibit a delayed recovery following antibody-mediated platelet depletion, due to impaired platelet production from megakaryocytes in the bone marrow. 52 This impairment is attributed to a lack of polarity of the leading edge of migrating megakaryocytes, mediated by the polarized compartmentalization of stromal-derived factor-1 (SDF-1) chemokine receptor CXCR4, and increased adhesion to extracellular matrix proteins in vitro. 53 As a consequence, PECAM-1-deficient megakaryocytes exhibit aberrant spatial distribution in the bone marrow following antibody-mediated platelet depletion. 52 The biological functions of PECAM-1 extend beyond that of simply regulating platelet and megakaryocyte function. Numerous studies have highlighted the importance of PECAM-1 in a broad range of cell types, including endothelial cells, hematopoietic and immune cells, 54 all of which contribute to the overall phenotype of Pecam1 -/-mice.
G6b-B -more than just a platelet inhibitor
Structure and function
The identification of G6b-B came almost a decade after that of PECAM-1, 55 and establishing its role in platelet function took a further 10 years. Restricted to platelets and megakaryocytes, G6b-B is one of a number of predicted variants (A-E) that arise from differential splicing ( Figure 5 ). These are either transmembrane-containing (G6b-A and -B)
or potentially secreted (G6b-C, -D and -E). 56 G6b-A and -B are both expressed in human platelets and have identical extracellular and transmembrane domains, but only the -B isoform contains the consensus ITIM and ITSM. Two other isoforms, G6b-F and -G, have been predicted, but are likely not expressed as they contain intronic sequences within an alternative C-terminus.
All G6b isoforms have a single variable-type Ig-like (IgV) domain and are Nglycosylated (one predicted site in humans and two in mice). 19, 56, 57 Human G6b-B has a classical ITIM consensus sequence at the membrane proximal tyrosine (Y194) and an ITSM (Y220) at the C-terminus ( Figure 5 and Table 2 ). Two PRRs in the juxtamembrane region may provide docking sites for SH3 domain-containing proteins, but this remains to be
proven. An inhibitory role for G6b-B was supported by the observation that phosphorylated G6b-B isolated from pervanadate-treated COS-7 cells co-immunoprecipitated with both Shp1
and Shp2, 56 interactions that have since been verified in both human and mouse platelets. 18, 19, 57, 58 Antibody-mediated cross-linking of G6b-B also promoted Shp1 recruitment and attenuation of CRP-and ADP-induced platelet aggregation and Ca 2+ release.
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In vitro assays showed G6b-B to bind the physiological anti-coagulant heparin with a predicted affinity of 30 nM, 59 comparable to the heparin-anti-thrombin III interaction, 60 assuming a 15 kDa average molecular weight for heparin. This interaction is unexpected as G6b-B lacks a heparin-binding consensus sequence. 59, 61, 62 However, the ectodomain of G6b-B has a theoretical pI > 10, most likely giving it a positive charge at neutral pH, which may account for the interaction with highly negatively charged heparin. Heparin is released by mast cells in the sub-endothelial matrix, and interacts with a variety of proteins, including plasma proteins, receptors and cytokines to modulate biological and physiological processes.
The best known function of heparin is as a cofactor of antithrombin III, conferring a 1,000-fold increase in its inhibitory function of thrombin. 63 The physiological significance of the interaction of heparin with G6b-B remains to be determined.
Mouse Models
With the exception of glycosylation, both mouse and human G6b-B are very similar in terms of expression, amino acid sequence (71% identity, 79% similarity), tyrosine phosphorylation, and binding of Shp1 and Shp2. 57 To determine the physiological function of G6b-B, constitutive and conditional KO mouse models (G6b -/-and Pf4-Cre + ;G6b fl/fl , respectively) role for G6b-B in regulating signaling from GPVI-FcR -chain and the hemi-ITAMcontaining podoplanin receptor CLEC-2 was found. 57 One of the most striking and unique features of G6b -/-mice is a dramatic reduction in platelet counts. This could be explained by a combination of reduced platelet recovery following antibody-mediated platelet depletion, supported by a reduction in G6b -/-megakaryocyte proplatelet formation, and enhanced platelet clearance, due to platelets being pre-activated and having surface antibodies bound, targeting them for destruction. 57 Together, these defects contributed to a 77% drop in platelet count. It is unlikely these effects are due to loss of G6b-B expression in other cell types as G6b-B is highly lineage specific ( Figure S1 ). 66 This is supported by the fact that G6b constitutive and conditional KO mouse models exhibit the same phenotype. 57, 64 Platelet surface receptor levels were also altered to varying degrees in G6b -/-mice, particularly GPVI, which was reduced by 82% relative to platelets from control mice. This was most likely attributable to increased receptor shedding mediated by the metalloproteinase ADAM10, which was increased by 36% in platelets from G6b -/-mice.
Collectively, platelet defects exhibited by G6b -/-mice culminated in increased bleeding rather than a prothrombotic phenotype that would be expected when deleting an inhibitor of platelet activation. Reduced platelet counts alone cannot fully explain the bleeding diathesis, as it has previously been shown that 80-90% reduction in platelet count has only mild bleeding and thrombotic consequences in mice. 67 However, when combined with reduced reactivity to collagen and thrombin, as is the case in G6b -/-mice, then increased bleeding is the outcome. Collagen was still able to elicit a reduced aggregation and ATP secretion response, owing to increased avidity and signaling through simultaneous binding of The physiological role of G6b-B has also now been validated in humans by Melhem and co-workers who characterized a family that exhibited an autosomal recessive thrombocytopenia. 69 Whole exome sequencing identified a nonsense mutation at the codon for residue C108 of human G6b resulting in a stop codon (p.C108*) and protein instability in transiently transfected K562 cells. 69 Patients exhibited severe thrombocytopenia, splenomegaly, increased number of megakaryocytes and fibrosis in bone marrow biopsies, similar to that reported in G6b KO and G6b-B diY/F mice. 57, 68 Interestingly, patients harboring this mutation were not reported to have a bleeding diathesis, whereas G6b -/-mice did show increased bleeding in a tail injury model, suggesting subtle differences underlie the phenotypes in humans and mice. Although causes of these defects reported in both species can be varied, it is worth noting that mice expressing human G6b-B do not exhibit any of these defects, 70 supporting the hypothesis that human and mouse G6b-B perform the same physiological functions and are critical regulators of platelet homeostasis.
Signal transduction
Considerable evidence exists to support the hypothesis that G6b-B is an important regulator of ITAM-containing receptor and integrin signaling, as well as platelet turnover. Similar to other ITIM-containing receptors, the current understanding is that G6b-B mediates its actions largely through recruitment of Shp1 and Shp2 to the plasma membrane, but there may be additional contributions from interactions with other effectors. 58 In a manner akin to the sequestration of Shp2/p85 complexes by PECAM-1, 44 it is possible that G6b-B may compete for effectors of ITAM-containing receptor signaling under resting conditions to prevent spurious activation signals. 58 However, these interactions have yet to be validated in platelets and the high affinity of G6b-B for Shp1 and Shp2 (nM range), 58 strongly suggest these interactions are likely to dominate.
Once recruited, PTPs are predicted to be activated and dephosphorylate key substrates, leading to an attenuation of tyrosine kinase signaling and cell activation.
However, the stoichiometry and downstream effects are probably more nuanced.
Interestingly, G6b-B is highly phosphorylated in resting platelets compared with other platelet ITIM-containing receptors. Thus, the biological function of G6b-B extends beyond that of inhibiting ITAMcontaining receptor signaling in platelets (Figure 4 ). Its potential for regulating platelet reactivity under resting conditions and apparent role in platelet production, coupled with specific megakaryocyte-platelet expression ( Figure S1 ), offers a novel therapeutic approach for managing thrombotic and hemorrhagic risk. It is likely that the elucidation of its endogenous ligand will greatly enhance our understanding of its function.
TLT-1 -the non-conventional
Structure/Function
Initially identified as the inhibitory analogue of the triggering receptor expressed on myeloid cells-1 (TREM-1) family of immune receptors, TLT-1 is a type I single IgV-containing surface receptor with an intracellular ITIM and ITSM-like sequence ( Figure 3 and Table 2 ). (Table 3) . 26, 27 However, unlike other platelet ITIM-containing receptors, TLT-1 is localized specifically in α-granules in resting platelets, and is up-regulated on the surface following thrombin-mediated activation.
20 Surprisingly, despite containing an ITIM and a nonconsensus ITSM (Table 2 and Figure 3 ), TLT-1 was found to have activating functions in a transiently transfected RBL-2H3 mast cell line, which showed enhanced FcRI-induced Ca 2+ mobilization, 77 while in platelets, antibody-mediated blocking of TLT-1 inhibits aggregation. 78 Platelet activation with thrombin results in the shedding of the ectodomain of TLT-1 referred to as soluble TLT-1 (sTLT-1), which is a competitive inhibitor of TREM-1 and has anti-inflammatory properties. 79 Indeed, sTLT-1 levels were substantially elevated in plasma from septic patients compared with healthy individuals, correlating with disseminated intravascular coagulation associated with sepsis. 80 Recombinant protein comprised solely of the ectodomain of TLT-1 was found to augment platelet aggregation and also to bind fibrinogen, suggesting fibrinogen is the physiological ligand of membrane bound TLT-1.
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Signal transduction
Phosphorylation of Y230 in the ITSM-like domain and Y266 in the ITIM of human TLT-1 is required for downstream signaling, the latter being critical for Shp2 recruitment in transiently-transfected pervanadate-treated RBL-2H3 cells. 77 An interaction with Shp1 was demonstrated in transiently transfected HEK293 cells upon discovery of the receptor, 75 but this was not verified by others. 77, 80 Shp1 and Shp2 interactions have not been validated in platelets, but pull-down assays using the cytoplasmic tail of the receptor did show an interaction with the ezrin/radixin/moesin (ERM) proteins in HEK293 and COS7 cells. The moesin interaction was also identified in human platelets by immunoprecipitation of full length TLT-1. 80 The ERM family links membrane proteins to the actin cytoskeleton and have important roles in lymphocyte activation and cytoskeleton remodeling during migration. 81 Interestingly, TLT-1 contributes to early actin polymerization, 82 indicating the ERM interaction may help to promote platelet activation. Thus, signaling via TLT-1 is distinct to that of other platelet ITIM-containing receptors.
Mouse Models
The KO mouse model of TLT-1 (Treml1
) revealed a critical role for this receptor in dampening the inflammatory response and facilitating platelet aggregation at sites of vascular injury. 80 This work confirmed an activating role for TLT-1 in platelets, notably aggregation responses to thrombin, collagen, ADP and U46619 were reduced, as was binding to fibrinogen, with a concomitant increase in tail bleeding times. 80 This is partially mediated by fibrinogen binding and TLT-1 linking to the platelet cytoskeleton, and presumably also by facilitating activation signals through an undefined mechanism. TLT-1-deficient mice also exhibit a 20% reduction in platelet count, suggesting a role in platelet production and/or clearance. 80 Lipopolysaccharide (LPS)-treated Treml1 -/-mice developed higher plasma levels of TNF and D-dimer compared with control mice and were more likely to succumb to LPS challenge, correlating with elevated levels of sTLT-1 in septic patients. 80 Despite the major advances in our understanding of the pathophysiological functions of TLT-1, several key questions remain, including the functional role of TLT-1 in platelets and megakaryocytes, how it signals and whether platelet TLT-1 regulates leukocyte localization and function.
Other ITIM-containing receptor contributors
In addition to PECAM-1, G6b-B and TLT-1, several other ITIM-containing receptors have been shown to regulate platelet activation and thrombus formation (Table 1) . CEACAM1
and CEACAM2 are expressed on a variety of tissues, including platelets (Figure S1 ), 66 and get upregulated on the surface of activated platelets, suggesting intracellular pools.
21,22
Findings from KO mouse models showed that both CEACAM1 and CEACAM2 attenuate ITAM receptor-mediated responses, presumably via Shp1 and Shp2, but paradoxically positively regulate integrin-mediated responses, 21,22,83,84 a recurring theme for platelet ITIMcontaining receptors. Larger and more stable thrombi following ferric chloride injury in vivo was also demonstrated in CEACAM1-and CEACAM2-deficient mice, indicating that the net functions of CEACAM1 and CEACAM2 is to limit thrombus growth. Platelet counts were normal in both CEACAM1-and CEACAM2-deficient mice, suggesting they are not required for platelet production and/or turnover under normal conditions. It would be interesting to determine whether deletion of both receptors has additive or synergistic effects on platelet activation and thrombosis phenotypes observed in single KO mice. However, the close proximity of the Ceacam1 and Ceacam2 genes on chromosome 7, makes generation of double-deficient mice technically challenging. 85 Controversially, CEACAM1 is not detected in human platelets by proteomics-based approaches and at low copy number in mouse platelets (868 copies per platelet). CEACAM2, found only in the murine genome, was also not detected in mouse platelets (Table 3) . 26, 27, 86 The reason for this discrepancy is not known, but may simply be a reflection of low abundance, masking of peptides during mass spectrometry or misassignment of peptides to other proteins following detection. Zoltan Nagy for data-mining proteomic and transcriptomic datasets for information regarding tissue distribution of ITIM-containing receptors presented in Table 3 and Figure S1 . 
